Compare
Cronos Group Inc. vs Natural Alternatives International Inc vs Marimed Inc. vs Niagen Bioscience, Inc.
| Latest fiscal year | Cronos Group Inc. CRON | Natural Alternatives International Inc NAII | Marimed Inc. MRMD | Niagen Bioscience, Inc. NAGE |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2026-06-30 | 2025-12-31 | 2025-12-31 |
| Revenue | $146.59M | $142.51M | $159.83M | $129.42M |
| Revenue growth (YoY) | +24.6% | +9.7% | +1.3% | +29.9% |
| Gross margin | 42.8% | 6.3% | 36.2% | 64.3% |
| Operating margin | -11.9% | -13.2% | -1.8% | 12.6% |
| Net margin | -6.4% | -14.5% | -9.1% | 13.4% |
| Net income | -$9.45M | -$20.70M | -$14.48M | $17.38M |
| EPS (Diluted) | -$0.02 | -$3.43 | -$0.04 | $0.20 |
| Operating cash flow | $25.87M | -$8.92M | $7.70M | $13.50M |
| Free cash flow | $149.0K | -$12.62M | $6.53M | n/a |
| Cash & equivalents | $791.79M | $7.39M | n/a | n/a |
| Total assets | $1.20B | $126.45M | $202.56M | $106.41M |
| Total liabilities | $54.18M | $76.49M | $137.83M | $29.87M |
| Shareholders' equity | $1.14B | $49.96M | $50.01M | $76.53M |
| Return on year-end equity | -0.8% | -41.4% | -29.0% | 22.7% |
| Shares outstanding | 381.59M | 6.27M | 396.91M | 79.71M |
Revenue, most recent five fiscal years
| Fiscal year | Cronos Group Inc. | Natural Alternatives International Inc | Marimed Inc. | Niagen Bioscience, Inc. |
|---|---|---|---|---|
| Latest | $146.59M Ended 2025-12-31 | $142.51M Ended 2026-06-30 | $159.83M Ended 2025-12-31 | $129.42M Ended 2025-12-31 |
| 1 year earlier | $117.61M Ended 2024-12-31 | $129.86M Ended 2025-06-30 | $157.71M Ended 2024-12-31 | $99.60M Ended 2024-12-31 |
| 2 years earlier | $87.24M Ended 2023-12-31 | $113.80M Ended 2024-06-30 | $148.60M Ended 2023-12-31 | $83.57M Ended 2023-12-31 |
| 3 years earlier | $86.75M Ended 2022-12-31 | $154.01M Ended 2023-06-30 | $134.01M Ended 2022-12-31 | $72.05M Ended 2022-12-31 |
| 4 years earlier | $64.56M Ended 2021-12-31 | $170.97M Ended 2022-06-30 | $121.46M Ended 2021-12-31 | $67.45M Ended 2021-12-31 |